leflunomide has been researched along with Nephrosis, Lipoid in 2 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Nephrosis, Lipoid: A kidney disease with no or minimal histological glomerular changes on light microscopy and with no immune deposits. It is characterized by lipid accumulation in the epithelial cells of KIDNEY TUBULES and in the URINE. Patients usually show NEPHROTIC SYNDROME indicating the presence of PROTEINURIA with accompanying EDEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| " During the treatment, 8 patients had adverse effects which could be well tolerated." | 1.39 | Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease. ( Huang, J; Li, J; Liu, G; Xu, R; Zhang, Y; Zhou, J, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhao, C | 1 |
| Cui, Z | 1 |
| Zhang, Y | 2 |
| Wang, F | 1 |
| Wang, X | 1 |
| Cheng, X | 1 |
| Meng, L | 1 |
| Liu, G | 2 |
| Zhao, M | 1 |
| Zhou, J | 1 |
| Li, J | 1 |
| Xu, R | 1 |
| Huang, J | 1 |
2 other studies available for leflunomide and Nephrosis, Lipoid
| Article | Year |
|---|---|
Leflunomide therapy for adult patients with steroid-dependent minimal change disease or primary focal segmental glomerulosclerosis.
Topics: Adult; Cyclosporine; Glomerulosclerosis, Focal Segmental; Humans; Leflunomide; Nephrosis, Lipoid; Ne | 2022 |
Efficacy and safety of leflunomide in treatment of steroid-dependent and steroid-resistant adult onset minimal change disease.
Topics: Adolescent; Adult; Drug Resistance; Female; Humans; Immunosuppressive Agents; Isoxazoles; Leflunomid | 2013 |